The Coronavirus Aid, Relief, and Economic Security (CARES) Act introduced significant changes to the drug regulatory landscape. Among these changes are new drug reporting requirements that drug manufacturers and distributors must adhere to. Reed Tech subject-matter experts, Gary Saner and Andrew Ethridge, presented a webinar providing a comprehensive overview of these requirements, their implications, and best practices for compliance. This free, educational webinar, is an exclusive benefit being offered to our current customers. 

Key Takeaways:

• A deep dive into the specific drug reporting provisions within the CARES Act
• Practical tips and resources for implementing effective drug reporting systems
• Reed Tech services for compliance

Watch the recording to gain a clear understanding of your responsibilities and ensure your organization is meeting the requirements presented by the CARES Act.

LexisNexis Reed Tech brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations, and ultimately achieve a competitive advantage for their business. Our Reed Tech suite of SingleSource™ for Medical Devices, SingleSource™ for Drug Products, and Navigator™ for Drug Labels enables life sciences companies to create product data management strategies and meet compliance deadlines on time. We are proud to directly support and serve these innovators in their endeavors to better humankind.